Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
April 30, 2015 12:34 PM EDT
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Incyte (NASDAQ: INCY) to $107.00 (from $84.00), citing a broad and robust pipeline.
Aschoff commented, "US Jakafi sales of $115.3 million included meaningful contribution from PV and beat consensus of $112.4 million. Ex-US Jakafi royalties of $15.7 million slightly missed consensus of $16.1 million. The 9% QoQ increase in Jakafi net sales was driven by 8% unit... More
April 30, 2015 10:03 AM EDT
Incyte (NASDAQ: INCY) reported Q1 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $159.28 million versus the consensus estimate of $155.21 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
...
More
